Ciprofibrate

Oral
Hyperlipidaemias

CrCl (mL/min)	Dosage
<30	Contraindicated.
30-80	Reduce dose to 100 mg every other day.

Severe: Contraindicated.

May be taken with or without food.

Severe hepatic and renal (CrCl <30 mL/min) impairment. Pregnancy and lactation. Concurrent use w/ other fibrates.

Patient w/ hypoalbuminaemia, nephrotic syndrome, hypothyroidism, alcohol abuse, history of hereditary muscular disorder, previous toxicity w/ other fibrates. Mild to moderate hepatic and renal impairment.

Urticaria, rashes, pruritus, eczema; elevated CPK levels, myalgia, myositis; headache, vertigo; nausea, vomiting, anorexia, diarrhoea, dyspepsia, abdominal pain; thrombocytopenia. Rarely, photosensitivity, alopecia, rhabdomyolysis, dizziness, somnolence, impotence, cholestasis, cytolysis, pneumonitis, pulmonary fibrosis, fatigue, leukocytopenia, pancreatitis, peripheral neuropathy.

This drug may cause dizziness, somnolence, and fatigue, if affected, do not drive or operate machinery.

Monitor for renal function. Perform periodic LFT every 3 mth for the 1st yr of treatment. Monitor for serum creatine phosphokinase (CPK) levels of patients reporting unexplained muscle pain, tenderness, or weakness.

Symptom: Rhabdomyolysis. Management: Symptomatic and supportive treatment. Employ gastric lavage.

Increased risk of muscle effects esp rhabdomyolysis w/ HMG-CoA reductase inhibitors. Reduced absorption w/ cholestyramine and colestipol. May increase the effects of phenytoin, tolbutamide and other sulphonylurea derivatives, and coumarin-like anticoagulants. May potentiate the effect of warfarin.
Potentially Fatal: Increased risk of rhabdomyolysis and myoglobinuria w/ other fibrates.

Description:
Mechanism of Action: Ciprofibrate is a fibric acid derivative that has a marked hypolipidaemic action. It reduces both LDL and VLDL cholesterols, leading to reduced levels of triglycerides, while increasing the HDL cholesterol levels.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: W/in 1-4 hr.
Distribution: Plasma protein binding: Approx 98%.
Excretion: Via urine (as unchanged drug and glucuronide conjugates). Elimination half-life: Approx 38-86 hr.

Store below 25°C.

Dyslipidaemic Agents

C10AB08 - ciprofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.

Anon. Ciprofibrate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/07/2016.

Buckingham R (ed). Ciprofibrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016.

Joint Formulary Committee. Ciprofibrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/07/2016.